New hope for CIDP: modified immune protein enters human testing
NCT ID NCT06798012
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study is testing TAK-411, a specially modified immune globulin, in 36 adults with CIDP, an autoimmune disease that attacks nerve insulation and causes muscle weakness. The main goal is to see if TAK-411 improves physical function over 24 weeks compared to historical placebo data. Participants receive infusions for up to a year and are followed for three more weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-411 (a modified immune globulin made from human plasma)
- What this could lead to
- If successful, TAK-411 could offer a new treatment option to improve physical function and reduce disability in people with CIDP.
- What could go wrong
- This is an early Phase 2 proof-of-concept study with only 36 participants, so results may not apply to everyone. The trial is open-label, meaning both patients and doctors know the treatment, which can bias results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
California Pacific Medical Center
RECRUITINGSan Francisco, California, 94109, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Fundacion Oftalmologica de Santander - FOSCAL
NOT_YET_RECRUITINGBucaramanga, 680001, Colombia
-
Fundacion Valle del Lili
NOT_YET_RECRUITINGCali, Valle del Cauca Department, 760032, Colombia
-
Hospital Universitario San Ignacio
NOT_YET_RECRUITINGBogotá, D.C., Colombia
-
Houston Methodist Research Institute
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
Neuro ClinicaS.A.S
NOT_YET_RECRUITINGMedellín, Antioquia, 50021, Colombia
-
Penn Blood Disorders Program - Hospital of The University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
The Curators of the University of Missouri on behalf of University of Missouri Health Care
RECRUITINGColumbia, Missouri, 65212-0001, United States
-
The Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
UF Health Neurology - Jacksonville
RECRUITINGJacksonville, Florida, 32209, United States
-
Universidad del Rosario
NOT_YET_RECRUITINGBogotá, 111711, Colombia
-
University Health Network
NOT_YET_RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
University of Calgary
NOT_YET_RECRUITINGCalgary, Alberta, T2N 4Z6, Canada
-
University of California San Diego
RECRUITINGLa Jolla, California, 92093, United States
-
University of South Florida
RECRUITINGTampa, Florida, 33612, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98195, United States
-
Visionary Investigators Network
RECRUITINGMiami, Florida, 33133, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.